Cellceutix’s IBD Therapy Brilacidin Progresses to Highest Dose Group in Phase 2 Trial

Cellceutix’s IBD Therapy Brilacidin Progresses to Highest Dose Group in Phase 2 Trial
Cellceutix says the ongoing Phase 2 clinical trial of its lead drug candidate Brilacidin has progressed to its third cohort (highest dose) to induce remission of mild-to-moderate ulcerative colitis, now that the study’s Safety Committee has reported satisfactory safety results with prior cohorts. In January, the Massachusetts company announced that it had completed enrollment of the second cohort of its Phase 2 open label

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

  1. mike wildt says:

    Results of this trial, combined with results from an ongoing phase 2 Brilacidin trial for oral mucositis in head and neck cancer patients and a completed phase 2B trial for ABSSSI that proved results comparable to daptomycin and it shows why many are excited about the possibilities of Brilacidin.
    Cellceutix also has a current phase 2B trials well underway with their psoriasis candidate drug Prurisol and their cancer drug Kevetrin.

    http://www.cellceutix.com/
    https://clinicaltrials.gov/ct2/results?term=cellceutix&Search=Search

    • mike wildt says:

      The oral mucositis trial is being conducted in Europe currently, and doesn’t show up on clinicaltrials.gov. We are awaiting interim results presently. Initial observations were very positive.

Leave a Comment

Your email address will not be published. Required fields are marked *